<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Post-induction <z:mpath ids='MPATH_58'>aplasia</z:mpath> for <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo>/<z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> is a high-risk period for invasive <z:e sem="disease" ids="C0026946" disease_type="Disease or Syndrome" abbrv="">fungal diseases</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The effectiveness of <z:chebi fb="2" ids="46081">fluconazole</z:chebi>, <z:chebi fb="0" ids="6076">itraconazole</z:chebi> solution, <z:chebi fb="0" ids="10023">voriconazole</z:chebi> and posaconazole prophylaxis used consecutively from December 1998 to January 2010 in patients with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo>/<z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> undergoing remission-induction chemotherapy was retrospectively evaluated </plain></SENT>
<SENT sid="2" pm="."><plain>A total of 216 consecutive patients received 573 prophylaxis courses </plain></SENT>
<SENT sid="3" pm="."><plain>Breakthrough-invasive <z:e sem="disease" ids="C0026946" disease_type="Disease or Syndrome" abbrv="">fungal disease</z:e> incidence in <z:chebi fb="2" ids="46081">fluconazole</z:chebi>, <z:chebi fb="0" ids="6076">itraconazole</z:chebi>, <z:chebi fb="0" ids="10023">voriconazole</z:chebi>, posaconazole recipients was 25%, 16%, 14% and 3%, respectively </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="10023">Voriconazole</z:chebi>/posconazole versus <z:chebi fb="2" ids="46081">fluconazole</z:chebi>/<z:chebi fb="0" ids="6076">itraconazole</z:chebi> combined was associated with significant reductions in breakthrough-invasive <z:e sem="disease" ids="C0026946" disease_type="Disease or Syndrome" abbrv="">fungal disease</z:e> incidence (20% vs. 8%, P=0.011), premature discontinuations (46% vs. 22% P&lt;0.001) and empiric antifungal treatment (31% vs. 8.5%, P&lt;0.001) </plain></SENT>
<SENT sid="5" pm="."><plain>Microbiologically confirmed <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> were molds </plain></SENT>
<SENT sid="6" pm="."><plain>Posaconazole compared to other drugs was associated with fewer courses requiring computed-tomography (43% vs. 26%, P&lt;0.001) </plain></SENT>
<SENT sid="7" pm="."><plain>Adoption of <z:chebi fb="0" ids="10023">voriconazole</z:chebi>/posaconazole has decreased invasive <z:e sem="disease" ids="C0026946" disease_type="Disease or Syndrome" abbrv="">fungal disease</z:e> incidence, empiric antifungal treatment and for posaconazole, computed-tomography demand, with effectiveness of posaconazole comparable to clinical trial experience </plain></SENT>
</text></document>